Ki-67 labelling index and invasiveness among anterior pituitary adenomas: Analysis of 103 cases using the MIB-1 monoclonal antibody

Journal of Clinical Pathology

Volumn 52, Issue 2, 1999, Pages 107-111

  Mastronardi, Luciano ^a,c   Guiducci, Antonio ^b   Spera, Cristina ^a   Puzzilli, Fabrizio ^a   Liberati, Fabio ^b   Maira, Giulio ^a  

^a Civilian Hospital   (Italy)

^b Civilia Hospital   (Italy)

^c NONE   (Italy)

Author keywords

Invasiveness; Ki 67; Pituitary adenomas

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADENOHYPOPHYSIS; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CAVERNOUS SINUS; CELL CYCLE G1 PHASE; CELL PROLIFERATION; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032892442     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.2.107     Document Type: Article

References (31)

1. 1 Asano K, Kubo O, Tajika Y, et al. The relationship between cell proliferation and secretory activity in pituitary adenomas. A review of 63 cases. No To Shinkei 1996;48:543-9.
2. 2 Atkin SL, Green VL, Hipkin LJ, et al. A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture. J Neurosurg 1997;87:85-8.
3. 3 Buchfelder M, Fahlbusch R, Adams EF, et al. Proliferation parameters for pituitary adenomas. Acta Neurochir Suppl (Wien) 1996;65:18-21.
4. 4 Daita G, Yonemasu Y. Dural invasion and proliferative potential of pituitary adenomas. Neurol Med Chir 1996;36: 211-14.
5. 5 Ekramullah SM, Saitoh Y, Arita N, et al. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 1996;138:1449-55.
6. 6 Knosp E, Kitz K, Steiner E, et al. Pituitary adenomas with parasellar invasion. Acta Neurochir Suppl (Wien) 1991;53: 65-71.
7. 7 Martins AN, Hayes GJ, Kempe LG. Invasive pituitary adenomas. J Neurosurg 1965;22:268-76.
8. 8 Pernicone PJ, Scheithauer BW. Invasive pituitary adenomas and pituitary carcinomas. In: Lloyd RV, ed. Surgical pathology of the pituitary gland. Philadelphia: WB Saunders, 1993: 121-36.
9. 9 Scheithauer BW, Kovacs KT, Laws ER, et al. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986;65:733-44.
10. 10 Selman WR, Laws ER, Scheithauer BW, et al. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-7.
11. 11 Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-107.
12. 12 Gandour-Edwards R, Kapadia SB, Janecka IP, et al. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 1995;8:160-4.
13. 13 Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg 1987;67:803-6.
14. 14 Nagashima T, Murovic JA, Hoshino T, et al. The proliferative potential of human pituitary tumors in situ. J Neurosurg 1986;64:588-93.
15. 15 Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989;25:927-30.
16. 16 McCormick D, Chong H, Hobbs C. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology 1993;22:355-60.
17. 17 Morimura T, Kitz K, Stein H. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neurooncol 1991;10:1-11.
18. 18 Parkins CS, Darling JL, Gill SS. Cell proliferation in serial biopsies through malignant brain tumors: measurement using Ki-67 antibody labelling. Br J Neurosurg 1991;5:289-98.
19. 19 Shiraishi T. Cell kinetic analysis of brain tumors using the monoclonal antibody Ki-67: in vitro and in situ study. Acta Med Okayama 1990;44:197-201.
20. 20 Tsanaclis AM, Robert F, Michaud J. The cycling pool of cells within human brain tumors: in situ cytokinetics using the monoclonal antibody Ki-67. Can J Neurol Sci 1991;18: 12-17.
21. 21 Zuber P, Hamou MF, de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988;22:364-8.
22. 22 Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:189-503.
23. 23 Henderson WR. The pituitary adenomata. A follow-up study of the surgical results in 338 cases (Dr Harvey Cushing's series). Br J Surg 1939;26:811-921.
24. 24 Jefferson G. Extrasellar extension of pituitary adenomas. Proc R Soc Med 1940;33:433-58.
25. 25 Trumble HC. Pituitary tumours. Observations on large tumours which have spread widely beyond the confines of the sella turcica. Br J Surg 1951;39:7-24.
26. 26 Jefferson G. The invasive adenomas of the anterior pituitary, 2nd ed. Springfield, Illinois: Charles C Thomas, 1972:56-60.
27. 27 Hall PA, Woods AL. Immunohistochemical markers of cellular proliferation: achievements, problems, and prospects. Cell Tissue Kinet 1990;23:505-22.
28. 28 Hops NJ, Bremm J, Bohl J, et al. Image analysis of proliferating cells in tumors of the human nervous system: an immunohistological study with the monoclonal antibody Ki-67. Neurosurgery 1994;35:917-23.
29. 29 Wintzer HO, Zipfel I, Schulte-Monting J, et al. Ki-67 immunostaining in human breast tumours and its relationship to prognosis. Cancer 1990;67:421-8.
30. 30 Hsu DW, Hakim F, Biller BMK, et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 1993;78:753-61.
31. 31 Shibuya M, Saito F, Miwa T, et al. Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berl) 1992;84:178-83.